A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection
Description
Phase
Phase 3 - a treatment has shown activity against a particular disease, where it is either added to existing treatment or compared to the standard treatment.Inclusion and Exclusion Criteria
- Genotype 3 HCV
- HCV RNA ≥10000 IU (International Unit)/mL
- Compensated Liver Cirrhosis
- BMI 18-40 kg/m2
- Previously treated for HCV or never treated for HCV
- Mixed infection of any genotype - Evidence of decompensated liver disease - Previous exposure to NS5A inhibitors Other protocol defined inclusion/exclusion criteria could apply
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI